Thyroid CancerNCT03006289
Relationship of Metabolic Syndrome and Its Components With Thyroid Cancer
An observational study of Thyroid Cancer, run by Lin Liao.
Trial summary
The purpose of this study is to investigate the association between metabolic syndrome (MS), body mass index (BMI), hyperglycemia, dyslipidemia, hypertension and thyroid cancer. Screen for the risk factors that affect the incidence of thyroid cancer. Read more about this study
- Who is it for?
- Ages 8 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Thyroid Cancer
- How many people
- 3,000 participants
- Where
- No sites listed yet
- Study dates
- Dec 2016to Nov 2017
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 8 to 80 years
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: patients undergone thyroid surgery
Who may be able to join
- patients undergone thyroid surgery
- signed the informed consent
Who cannot join
- 1.patients with no surgery
Trial locations and contacts
No sites are listed yet.
About this study
The purpose of this study is to investigate the association between metabolic syndrome (MS), body mass index (BMI), hyperglycemia, dyslipidemia, hypertension and thyroid cancer. Screen for the risk factors that affect the incidence of thyroid cancer.
- Conditions
- Thyroid Cancer
- Keywords
- Metabolic Syndrome, fasting plasma glucose
- Medical subject headings
- Thyroid Neoplasms, Metabolic Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| The thyroid cancer group | The postoperative pathology of thyroid is malignant | |
| The thyroid nodule group | The postoperative pathology of thyroid is benign |
What is being measured
The primary outcome is the main question the study is designed to answer.
lipids
Measured: before the thyroid surgery
Secondary outcomes (1)
glucose
Measured: before the thyroid surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Dec 2016 (estimated)
- Study startDec 2016
- Primary completionOct 2017 (estimated)
- Study completionNov 2017 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Thyroid CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Enrolment
- 3,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Lin Liao
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Lin Liao, Qianfoshan Hospital
- Investigators
- Lin Liao, MD, Study chair, Qianfoshan Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03006289
- Sponsor's protocol ID
- qfsnfm-003
- Status last verified
- Dec 2016
- First submitted
- 26 Dec 2016
- Last updated
- 30 Dec 2016
- Results posted
- No
- Data monitoring committee
- Yes
- Individual data sharing
- Yes
Publications
Yao J, Zhao J, Liu J, Jiang S, Guo S, Xu L, Zhang X, Sheng Q, Wang K, Liao L, Dong J. The relationships between thyroid functions of short-term rapid hypothyroidism and blood lipid levels in post-thyroidectomy patients of differentiated thyroid cancer. Front Endocrinol (Lausanne). 2023 Apr 27;14:1114344. doi: 10.3389/fendo.2023.1114344. eCollection 2023.
PubMed 37181036Zhao J, Tian Y, Jia Z, Yao J, Liao L, Dong J. Abnormal Glucose Metabolism Parameters and the Aggressiveness of Differentiated Thyroid Carcinoma: A Hospital-Based Cross-Section Study in China. Front Endocrinol (Lausanne). 2022 Mar 1;13:806349. doi: 10.3389/fendo.2022.806349. eCollection 2022.
PubMed 35299970Zhao J, Tian Y, Yao J, Gu H, Zhang R, Wang H, Liao L, Dong J. Hypercholesterolemia Is an Associated Factor for Risk of Differentiated Thyroid Cancer in Chinese Population. Front Oncol. 2021 Jan 28;10:508126. doi: 10.3389/fonc.2020.508126. eCollection 2020.
PubMed 33585179
Study at a glance
From the registry record, last updated by the sponsor on 30 Dec 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Relationship of Metabolic Syndrome and Its Components With Thyroid Cancer
- ClinicalTrials.gov ID
- NCT03006289
- Acronym / sponsor ID
- qfsnfm-003
- Conditions
- Thyroid Cancer
- Keywords
- Metabolic Syndrome, fasting plasma glucose
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 3,000 participants (estimated)
- Lead sponsor
- Lin LiaoUniversity, hospital or other
- Study start
- Dec 2016
- Primary completion
- Oct 2017 (estimated)
- Study completion
- Nov 2017 (estimated)
- First posted
- 30 Dec 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to investigate the association between metabolic syndrome (MS), body mass index (BMI), hyperglycemia, dyslipidemia, hypertension and thyroid cancer. Screen for the risk factors that affect the incidence of thyroid cancer.
Study design
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| The thyroid cancer group | – | –The postoperative pathology of thyroid is malignant |
| The thyroid nodule group | – | –The postoperative pathology of thyroid is benign |
Who may qualify
- Ages
- 8 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
- Study population
- patients undergone thyroid surgery
Key inclusion criteria (2 listed)
- patients undergone thyroid surgery
- signed the informed consent
Key exclusion criteria (1 listed)
- 1.patients with no surgery
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
lipids
Time frame: before the thyroid surgery
1 secondary outcome
glucose
Time frame: before the thyroid surgery
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Dec 2016.
- Derived from this study: PubMed 37181036Yao J, Zhao J, Liu J, Jiang S, Guo S, Xu L, Zhang X, Sheng Q, Wang K, Liao L, Dong J. The relationships between thyroid functions of short-term rapid hypothyroidism and blood lipid levels in post-thyroidectomy patients of differentiated thyroid cancer. Front Endocrinol (Lausanne). 2023 Apr 27;14:1114344. doi: 10.3389/fendo.2023.1114344. eCollection 2023.
- Derived from this study: PubMed 35299970Zhao J, Tian Y, Jia Z, Yao J, Liao L, Dong J. Abnormal Glucose Metabolism Parameters and the Aggressiveness of Differentiated Thyroid Carcinoma: A Hospital-Based Cross-Section Study in China. Front Endocrinol (Lausanne). 2022 Mar 1;13:806349. doi: 10.3389/fendo.2022.806349. eCollection 2022.
- Derived from this study: PubMed 33585179Zhao J, Tian Y, Yao J, Gu H, Zhang R, Wang H, Liao L, Dong J. Hypercholesterolemia Is an Associated Factor for Risk of Differentiated Thyroid Cancer in Chinese Population. Front Oncol. 2021 Jan 28;10:508126. doi: 10.3389/fonc.2020.508126. eCollection 2020.
- Individual participant dataSharing planned: Yes
Related trials for Thyroid Cancer
Recruiting
NIRAF-Guided Parathyroid Identification During Thyroidectomy
Hypocalcemia, Hypoparathyroidism
Active, not recruitingPhase 1
Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers
Bladder Carcinoma, Cervical Carcinoma
Not yet recruitingPhase 1/2
177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
Thyroid Cancer
RecruitingObservational study
DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study
Pleuropulmonary Blastoma, Cystic Nephroma
Recruiting
Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules
Thyroid Gland Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Lin Liao, MD study chair
Qianfoshan Hospital
Questions about this trial
What is this clinical trial studying?
An observational study of Thyroid Cancer, run by Lin Liao.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 30 Dec 2016. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Lin Liao, MD (8615168888260, liaolin@medmail.com.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
lipids (time frame: before the thyroid surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT03006289, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Dec 2016.